Marker Therapeutics, Inc.

For the period ended Dec 31, 2024. Filed Mar 31, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 31, 2025

MRKR$0.99+10.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents


FORWARD LOOKING STATEMENTS · ii
Part I · ·
Item 1.	Business	1
Item 1A.	Risk Factors	28
Item 1B.	Unresolved Staff Comments	66
Item 1C.	Cybersecurity	66
Item 2.	Properties	67
Item 3.	Legal Proceedings	67
Item 4.	Mine Safety Disclosure	67
Part II
Item 5.	Market For Registrant’s Common Equity, Related Stockholder Matters And Issuer Purchases Of Equity Securities	68
Item 6.	[Reserved]	69
Item 7.	Management’s Discussion And Analysis Of Financial Condition And Results Of Operations	69
Item 7A.	Quantitative And Qualitative Disclosures About Market Risk	82
Item 8.	Financial Statements	82
Item 9.	Changes In And Disagreements With Accountants On Accounting And Financial Disclosure	82
Item 9A.	Controls And Procedures	82
Item 9B.	Other Information	83
Item 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	84
Part III
Item 10.	Directors, Executive Officers And Corporate Governance	85
Item 11.	Executive Compensation	85
Item 12.	Security Ownership Of Certain Beneficial Owners And Management And Related Stockholder Matters	85
Item 13.	Certain Relationships And Related Transactions, And Director Independence	85
Item 14.	Principal Accounting Fees And Services	85
Part IV
Item 15.	Exhibits, Financial Statement Schedules	86
	Signatures	90

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.

About this filing

Table of Contents